Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Avoid positioning this stack as a treatment or cure for inflammatory disease
Patients currently using injectable GLP-1 medications should follow the specific administration instructions provided with their prescribed product
The letter emphasized several key points: Bulk compounding of semaglutide and tirzepatide is no longer permitted because FDA removed these products from the national shortage list Marketing terms such as generic Ozempic, semaglutide pills or vitamin-enhanced GLP-1 injections may violate state consumer-protection law when referring to non-approved formulations Misleading advertising of unapproved GLP-1 products falls under the Connecticut Unfair Trade Practices Act (CUTPA) Although the letter did not accuse any specific provider of wrongdoing, Connecticut placed clinics on formal notice that the GLP-1 market was under review and that enforcement would follow if risky practices continued
For retatrutide specifically, 12 mg weekly produces the largest loss but has the highest GI dropout rate, and 9 mg weekly gives nearly the same loss with better tolerability
